Showing 1711-1720 of 4063 results for "".
- Cloudbreak Pharma Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pingueculahttps://modernod.com/news/cloudbreak-pharma-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula/2482896/Cloudbreak Pharma announced positive topline results from its phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. The multicenter, randomized, double-maske
- Ashvattha Therapeutics Presents Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Diseasehttps://modernod.com/news/ashvattha-therapeutics-present-positive-phase-2-results-for-subcutaneous-migaldendranib-in-retinal-vascular-disease-at-arvo/2482795/Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the
- CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmologyhttps://modernod.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November
- Eversight-Led Research Confirms Presence of SARS-CoV-2 in Postmortem Ocular Tissuehttps://modernod.com/news/eversight-led-research-confirms-presence-of-sars-cov-2-in-postmortem-ocular-tissue/2478578/Eversight announced research findings showing a small but noteworthy prevalence of SARS-CoV-2 in ocular tissues from individuals who died from COVID-19. The findings were presented Nov. 7 at the
- FDA Approves Quidel’s Sofia 2, First Antigen Test to Help in the Rapid Detection of COVID-19https://modernod.com/news/quidel-receives-emergency-authorization-for-rapid-antigen-covid-19-diagnostic-assay/2477735/Quidel, which makes diagnostic tests for a variety of conditions including acute conjunctivitis and dry eye disease, announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2
- Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucomahttps://modernod.com/news/nicox-reports-positive-results-of-secondary-analyses-from-phase-2-trial-further-highlighting-potential-of-ncx-470-in-glaucoma/2477029/Nicox announced the results of secondary analyses of its Dolomites phase 2 trial with NCX 470 for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Positive topline results were
- Nicox Completes Enrollment of NCX 4251 Phase 2 Trial with Topline Results on Track for Q4 2019https://modernod.com/news/nicox-completes-enrolment-of-ncx-4251-phase-2-trial-with-top-line-results-on-track-for-q4-2019/2476918/Nicox SA announced that it has completed enrollment in its multicenter, dose escalating, US phase 2 clinical trial evaluating the safety and tolerability of NCX 4251 in acute exacerbations of blepharitis. The primary objective of this
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ
- Full Phase 2 Results Published Showing Efficacy, Safety, & Durability of Faricimab in DMEhttps://modernod.com/news/full-phase-2-results-published-showing-efficacy-safety-durability-of-faricimab-in-diabetic-macular-edema/2476497/Full results from Roche and Genentech’s phase 2 BOULEVARD study have been published in the journal, Ophthalmology. The study shows the investigational molecule, faricimab, was superior to ranibizumab in achieving
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH